drugset
drugset / Trial / NCT07233018

A Clinical Study to Explore the Safety and Efficacy of CT0991 in Relapsed/ Refractory Acute Myeloid Leukemia

NCT07233018 ↗

Phase 1 Not yet recruiting 24 enrolled MEI HENG
NaSingle-groupOpen-labelTreatment

Summary

A Clinical Study to Investigate the Safety and Efficacy of CT0991 in Patients with Relapsed/Refractory Acute Myeloid Leukemia.

Timeline

Start
2025-11-18
Primary completion
2026-06-30
Completion
2027-05-30

Drugs

EvaluationDrugModalityDoseRoute
Subject CT0991 Unknown — —

Indications

acute myeloid leukemia